Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT path...

Full description

Bibliographic Details
Main Authors: Elizabeth K. Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch, Ursula A. Matulonis, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Joyce F. Liu
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:Gynecologic Oncology Reports
Subjects:
MK-2206
AKT inhibitor
PI3K/AKT pathway
PTEN
Platinum resistant ovarian cancer
Serous ovarian carcinoma
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578920300126

Internet

http://www.sciencedirect.com/science/article/pii/S2352578920300126

Similar Items